ScripGerman multinational Miltenyi Biotec’s senior leadership sees significant opportunities for India in the cell and gene therapy space if it can get things right in terms of shaping the regulatory frame
Pink SheetEngland’s health technology assessment institute, NICE, has reversed its rejection of the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) for treating relapsed or refractory large B-cell lympho
ScripGilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do
Pink SheetThe scope and technical complexity of assessing the risk of secondary malignancies in gene therapy recipients looms over the US Food and Drug Administration’s focus on the role of insertion site analy